O6Z Lonza
- 79.970
- 0.0000.00%
Lonza News
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug
Acumen Pharmaceuticals (ABOS) said Thursday that it has signed a collaboration agreement with healthcare manufacturing organization Lonza to develop and commercialize sabirnetug to treat Alzheimer's d
Lonza CEO Appointment to Be Well Received -- Market Talk
0735 GMT - Lonza Group's appointment of Wolfgang Wienand as its new CEO will likely get a favorable market reaction given that he is an external candidate who brings a wealth of experience in the drug
Lonza Group Appoints New CEO; Seeks Lifting of Trading Halt
Lonza Group (SGX:O6Z) appointed Wolfgang Wienand as chief executive, succeeding Albert Baehny, according to a Singapore bourse filing on Tuesday. Wienand, who will join the drug manufacturing company
Singaporean Shares Rise Tracking Global Gains; Top Glove's Shares Up 9% as Losses Shrink
Singapore shares finished marginally higher on Wednesday, following overnight gains in global markets. During the day, the benchmark Singapore Strait Times Index ranged between 3,174.13 and 3,188.06,
Lonza Group to Acquire Biologics Site in US for $1.2 Billion
Lonza Group (SGX:O6Z) agreed to acquire the Genentech manufacturing facility in Vacaville, US, from multinational healthcare company Roche for $1.2 billion, according to a filing with the Singapore ex
Lonza's Chair Succession Shouldn't Derail CEO Search -- Market Talk
Lonza Group's proposed chairman succession shouldn't affect a decision on a new CEO, which is key to rebuild confidence in the Swiss life-sciences company, Jefferies analysts say in a research note.
Lonza Names Heineken's Jean-Marc Huet as Next Chairman
Lonza Group has proposed Jean-Marc Huet, currently chairman of Dutch brewer Heineken, as its next chair to replace Albert Baehny.
Lonza Group's CEO Steps Down
Lonza Group's (SGX:O6Z) chief executive officer, Pierre-Alain Ruffieux, will step down from the role and leave the company at the end of the month by mutual agreement, according to a Monday bourse disclosure.
Lonza Group's Profit Declines 17.5% in H1 Despite Revenue Jump
Lonza Group (SGX:O6Z) posted a profit of 411 million Swiss francs in the first half of the year, 17.5% lower from the 498 million francs it posted a year earlier.
Lonza Group Profit Balloons 89% in H1 as Sales Rises 17%
03:08 AM EDT, 07/22/2022 (MT Newswires) -- Lonza Group (SGX:O6Z) posted a profit of 498 million Swiss francs ($514.9 million) in the first half of the year, an increase of 89.4% from the 263 million f
Lonza Group Investing $522 Million to Construct Drug Product Fill and Finish Facility in Switzerland
04:04 AM EDT, 07/01/2022 (MT Newswires) -- Lonza Group (SGX:O6Z) is investing 500 million Swiss francs ($522.2 million) to construct a large-scale commercial drug product fill and finish facility in S
Press Release: Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates $14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Stead
Lonza to Buy Service Unit of Exosomics
11:32 PM EDT, 11/02/2021 (MT Newswires) -- Lonza Group (LONN.SW) said Tuesday it agreed to purchase biotech company Exosomics' service unit for an undisclosed amount. The acquisition will include a s
Codiak BioSciences Sells Exosome Manufacturing Facility to Lonza
10:55 AM EDT, 11/02/2021 (MT Newswires) -- Codiak BioSciences (CDAK) has sold its exosome manufacturing facility in Lexington, Massachusetts to Lonza, a manufacturing company for the pharma, biotech
Worldwide Antibody Drug Conjugates Contract Manufacturing Industry to 2028 - Rising Prevalence of Cancer is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Link
Global Investigational New Drug CDMO Market (2021 to 2028) - Featuring Catalent, Lonza and Patheon Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Contract Development, Contract Manu
Lonza Group to Purchase Specialized Manufacturing Plant From Codiak BioSciences
08:48 AM EDT, 11/02/2021 (MT Newswires) -- Lonza Group (LONN.SW) on Tuesday said that it agreed to acquire an exosome manufacturing facility in Lexington, Mass., in the US, from Codiak BioSciences fo
Lonza to Acquire Service Unit in Italy, Manufacturing Facility in US
By Cecilia Butini Lonza Group AG said Tuesday that it has acquired a service unit including laboratories in Italy and a manufacturing facility in the U.S. The Swiss life-sciences company s
BRIEF-Lonza Says To Acquire And Operate Codiak's Lexington Facility In U.S.
Nov 2 (Reuters) - Lonza Group AG LONN.S :* LONZA TO ACQUIRE AND OPERATE CODIAK'S LEXINGTON, MA (US) FACILITY AND BECOME STRATEGIC MANUFACTURING PARTNER FOR CODIAK'S PIPELINE* LONZA AND CODIAK TO ESTA
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak's pipelineLonza and Codiak to establish a Center of Excellence focused on ex
Analysis
Price Target
No Data
